Kestrel Therapeutics
PrivateLast Round
Corporate Funding
Apr 28, 2026
Total Funding Raised
$48M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Kestrel Therapeutics operates in Healthcare & Life Sciences and is based in Watertown, Massachusetts. Its latest recorded funding round was a VC Round in August 2025.
Kestrel Therapeutics is a biotechnology company that develops small-molecule inhibitors targeting mutant KRAS proteins for the treatment of intractable cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Kestrel Therapeutics Comparables
Compare Kestrel Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Quanta Therapeutics | 85% | |
| Jacobio Pharmaceuticals Group Co Ltd | 80% | |
| Revolution Medicines | 79% |
For institutional investors. Book with your work email.
Kestrel Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Corporate Funding | Apr 28, 2026 | ||||
| VC Round | Aug 12, 2025 | ||||
| Convertible Debt | Feb 21, 2025 | ||||
| Series A | Dec 1, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Kestrel Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| S32 | Series A |
| Cormorant Asset Management | Series A |
| Santé Ventures | VC Round, Series A |
| Pfizer | Series A |
| Cormorant Asset Management | Series A |
| Pfizer Ventures | VC Round, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 28, 2026
AbbVie led the corporate funding round.
- Aug 12, 2025
$5M raised from Pfizer Ventures and Santé Ventures.
For institutional investors. Book with your work email.
Kestrel Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Kestrel Therapeutics's valuation, stock price, and market status.
Is Kestrel Therapeutics a public or private company?
Kestrel Therapeutics is a private company.
What is the current stock price of Kestrel Therapeutics?
Kestrel Therapeutics is a private company, so its shares have no public market price. Caplight tracks Kestrel Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Kestrel Therapeutics worth (valuation)?
Valuation information for Kestrel Therapeutics is not publicly available.
Can I buy Kestrel Therapeutics stock?
Kestrel Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Kestrel Therapeutics's last funding round?
Kestrel Therapeutics's most recent funding round was Corporate Funding on April 28, 2026.
Who are the main investors in Kestrel Therapeutics?
Key investors in Kestrel Therapeutics include S32, Cormorant Asset Management, Santé Ventures, Pfizer, Cormorant Asset Management.
Will Kestrel Therapeutics IPO soon?
No public IPO plans have been announced for Kestrel Therapeutics.
How can I track Kestrel Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Kestrel Therapeutics's shares on secondary markets.